01.28.10
Cenestra Health, New Haven, CT, has received U.S. patent #7652068, entitled "Omega 3 Fatty Acid Formulations," from the U.S. Patent and Trademark Office. The patent covers a unique, high-purity formulation of the omega 3 fatty acids EPA and DHA. Scientific data obtained from third party academic laboratories indicates that Cenestra Health's proprietary omega 3 formulations simultaneously decrease key pro-inflammatory mediators implicated in cardiovascular and inflammatory disorders while also increasing expression of a key nerve growth factor, brain-derived neurotrophic factor (BDNF), which is associated with antidepressant properties.